Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing. Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-105, an anti-TNF-alpha antibody to treat psoriatic arthritis; RT-102, a parathyroid hormone that is in preclinical studies for the treatment of osteoporosis; RT-109, a human growth hormone to treat growth hormone deficiency; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-106, a basal insulin for the treatment of type 2 diabetes. The company was incorporated in 2012 and is headquartered in San Jose, California.

Rani Therapeutics Holdings, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

~ CONTINUES TO ADVANCE RT-114 IN THE CLINIC WITH FIRST PARTICIPANTS DOSED IN THE PHASE 1A EXPANSION COHORT; ADDITIONAL DATA EXPECTED BY END OF 2026 ~ ~ ANNOUNCED POSITIVE INITIAL PHASE 1A DATA FOR RT-114, WITH ORAL BIOAVAILABILITY ACHIEVING SYSTEMIC EXPOSURE GREATER THAN 150% RELATIVE TO MATCHED SUBCUTANEOUS DOSING ~ ~ COMPLETED A $20 MILLION REGISTERED DIRECT OFFERING ~ ~ EXPANDED OBESITY PIPELINE THROUGH NEW RESEARCH AND DEVELOPMENT COLLABORATION WITH PEGBIO TO EXPLORE ORAL DELIVERY OF NOVEL OBESITY AND METABOLIC DISEASE MOLECULES USING THE RANIPILL PLATFORM ~ ~ APPOINTED NICHOLAS MAESTAS AS CHIEF FINANCIAL OFFICER AND MICHELLE GILSON TO BOARD OF DIRECTORS ~ SAN JOSE, CALIF., AUG. 13, 2026 (GLOBE NEWSWIRE) -- RANI THERAPEUTICS HOLDINGS, INC. (NASDAQ: RANI), A CLINICAL-STAGE BIOTHERAPEUTICS COMPANY FOCUSED ON ORAL DELIVERY OF BIOLOGICS, TODAY REPORTED FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2026, AND PROVIDED A CORPORATE UPDATE.

RANI THERAPEUTICS REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS; PROVIDES CORPORATE UPDATE

SAN JOSE, CALIF., AUG. 10, 2026 (GLOBE NEWSWIRE) -- RANI THERAPEUTICS HOLDINGS, INC. (NASDAQ: RANI), A CLINICAL-STAGE BIOTHERAPEUTICS COMPANY FOCUSED ON ORAL DELIVERY OF BIOLOGICS, TODAY ANNOUNCED THAT THE COMPANY'S MANAGEMENT TEAM WILL PARTICIPATE IN THE UPCOMING CANACCORD GENUITY 46TH ANNUAL GROWTH CONFERENCE. DETAILS BELOW:

RANI THERAPEUTICS TO PARTICIPATE IN THE CANACCORD GENUITY 46TH ANNUAL GROWTH CONFERENCE

SAN JOSE, CALIF., JULY 20, 2026 (GLOBE NEWSWIRE) -- RANI THERAPEUTICS HOLDINGS, INC. (RANI THERAPEUTICS; RANI OR THE COMPANY) (NASDAQ: RANI), A CLINICAL-STAGE BIOTHERAPEUTICS COMPANY FOCUSED ON THE ORAL DELIVERY OF BIOLOGICS AND DRUGS, TODAY REPORTED THAT IT GRANTED AN EQUITY AWARD IN THE FORM OF A STOCK OPTION TO PURCHASE 2,000,000 SHARES OF RANI CLASS A COMMON STOCK TO NICHOLAS MAESTAS, RANI'S NEW CHIEF FINANCIAL OFFICER, AS AN INDUCEMENT MATERIAL TO HIS ACCEPTANCE OF EMPLOYMENT WITH RANI.

RANI THERAPEUTICS REPORTS INDUCEMENT GRANT UNDER NASDAQ LISTING RULE 5635(C)(4)

RT-114 ACHIEVED SYSTEMIC EXPOSURE GREATER THAN 150% RELATIVE TO A MATCHED 12MG SUBCUTANEOUS DOSE OF PG-102 NO ADVERSE EVENTS ATTRIBUTED TO RANIPILL CAPSULE; TREATMENT-RELATED ADVERSE EVENTS WERE MILD AND CONSISTENT WITH THE GLP-1/GLP-2 AGONIST CLASS OF THERAPEUTICS PHASE 1A STUDY EXPANDED WITH AN ADDITIONAL COHORT TO FURTHER DEFINE THE ORAL-TO-SUBCUTANEOUS PHARMACOKINETIC RELATIONSHIP AHEAD OF A PLANNED PHASE 1B REPEAT-DOSE STUDY IN PATIENTS WITH OBESITY SAN JOSE, CALIF., JULY 15, 2026 (GLOBE NEWSWIRE) -- RANI THERAPEUTICS HOLDINGS, INC. (NASDAQ: RANI), A CLINICAL-STAGE BIOTHERAPEUTICS COMPANY FOCUSED ON ORAL DELIVERY OF BIOLOGICS, TODAY REPORTED POSITIVE INITIAL DATA FROM THE ONGOING PHASE 1 STUDY OF RT-114, AN ORALLY ADMINISTERED RANIPILLCAPSULE DELIVERING PG-102, A GLP-1/GLP-2 DUAL AGONIST BEING DEVELOPED BY PROGEN CO., LTD.

RANI THERAPEUTICS ANNOUNCES POSITIVE INITIAL PHASE 1A DATA FOR RT-114 FOR THE TREATMENT OF OBESITY, WITH ORAL BIOAVAILABILITY EXCEEDING MATCHED SUBCUTANEOUS DOSING

~ COLLABORATION WILL LEVERAGE THE RANIPILL PLATFORM TO EXPLORE ORAL DELIVERY OF PEGBIO'S PROPRIETARY PORTFOLIO OF NOVEL OBESITY AND METABOLIC DISEASE MOLECULES ~

RANI THERAPEUTICS ANNOUNCES RESEARCH AND DEVELOPMENT COLLABORATION WITH PEGBIO TO EXPAND OBESITY PIPELINE ACROSS MULTIPLE NOVEL CANDIDATES

SAN JOSE, CALIF., JUNE 29, 2026 (GLOBE NEWSWIRE) -- RANI THERAPEUTICS HOLDINGS, INC. (RANI THERAPEUTICS; RANI OR THE COMPANY) (NASDAQ: RANI), A CLINICAL-STAGE BIOTHERAPEUTICS COMPANY FOCUSED ON THE ORAL DELIVERY OF BIOLOGICS AND DRUGS, TODAY ANNOUNCED THE APPOINTMENT OF NICHOLAS MAESTAS AS CHIEF FINANCIAL OFFICER, EFFECTIVE IMMEDIATELY.

RANI THERAPEUTICS APPOINTS NICHOLAS MAESTAS AS CHIEF FINANCIAL OFFICER

SAN JOSE, CALIF., MAY 26, 2026 (GLOBE NEWSWIRE) -- RANI THERAPEUTICS HOLDINGS, INC. (RANI THERAPEUTICS OR RANI) (NASDAQ: RANI), A CLINICAL-STAGE BIOTHERAPEUTICS COMPANY FOCUSED ON THE ORAL DELIVERY OF BIOLOGICS AND DRUGS, TODAY ANNOUNCED THAT IT HAS ENTERED INTO A SECURITIES PURCHASE AGREEMENT LED BY A SOVEREIGN WEALTH FUND, ALONG WITH OTHER NEW AND EXISTING HEALTHCARE-FOCUSED FUNDS FOR THE PURCHASE AND SALE OF 12,476,637 SHARES OF RANI THERAPEUTICS' CLASS A COMMON STOCK AT A PURCHASE PRICE OF $1.07 PER SHARE AND PRE-FUNDED WARRANTS TO PURCHASE 6,214,953 SHARES OF CLASS A COMMON STOCK AT A PURCHASE PRICE OF $1.0699 PER PRE-FUNDED WARRANT IN A REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET UNDER NASDAQ RULES.

RANI THERAPEUTICS HOLDINGS, INC. ANNOUNCES PRICING OF $20.0 MILLION REGISTERED DIRECT OFFERING OF CLASS A COMMON STOCK PRICED AT-THE-MARKET UNDER NASDAQ RULES

- CONTINUED ADVANCEMENT OF THE ONGOING PHASE 1 STUDY OF RT-114 VIA RANIPILL FOR THE TREATMENT OF OBESITY IN COLLABORATION WITH PROGEN 

RANI THERAPEUTICS REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS; PROVIDES CORPORATE UPDATE; ANNOUNCES CFO TRANSITION

SAN JOSE, CALIF., MAY 12, 2026 (GLOBE NEWSWIRE) -- RANI THERAPEUTICS HOLDINGS, INC. (RANI THERAPEUTICS OR RANI) (NASDAQ: RANI), A CLINICAL-STAGE BIOTHERAPEUTICS COMPANY FOCUSED ON THE ORAL DELIVERY OF BIOLOGICS AND DRUGS, TODAY ANNOUNCED THAT THE COMPANY'S MANAGEMENT TEAM WILL PARTICIPATE IN THE UPCOMING H.C.

RANI THERAPEUTICS TO PARTICIPATE IN THE H.C. WAINWRIGHT ANNUAL BIOCONNECT INVESTOR CONFERENCE

SAN JOSE, CALIF., APRIL 09, 2026 (GLOBE NEWSWIRE) -- RANI THERAPEUTICS HOLDINGS, INC. (RANI THERAPEUTICS OR RANI) (NASDAQ: RANI), A CLINICAL-STAGE BIOTHERAPEUTICS COMPANY FOCUSED ON THE ORAL DELIVERY OF BIOLOGICS AND DRUGS, TODAY ANNOUNCED THE APPOINTMENT OF DR. SARA KENKARE-MITRA AS A STRATEGIC ADVISOR. DR. KENKARE-MITRA BRINGS NEARLY THREE DECADES OF EXPERIENCE IN BIOLOGICS AND SMALL MOLECULE DRUG DISCOVERY AND DEVELOPMENT, WITH A PROVEN TRACK RECORD OF GLOBAL REGULATORY APPROVALS AND COMMERCIAL LAUNCHES ACROSS ONCOLOGY, IMMUNOLOGY, NEURODEGENERATION, OPHTHALMOLOGY, AND RESPIRATORY DISEASES.

Rani Therapeutics Holdings, Inc.

RANI

Price

Financial Reports

No items found.

Press Releases

Rani Therapeutics Holdings, Inc.

RANI.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

RANI